Co-Authors
This is a "connection" page, showing publications co-authored by Peter McCullough and Alberto Palazzuoli.
Connection Strength
5.107
-
Impact of renin-angiotensin-aldosterone system inhibitor continuation on outcomes for patients with severe coronavirus disease 2019 manifestations. J Hypertens. 2021 08 01; 39(8):1725-1726.
Score: 0.959
-
Screening, detection, and management of heart failure in the SARS-CoV2 (COVID-19) pandemic. Heart Fail Rev. 2021 07; 26(4):973-979.
Score: 0.923
-
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome. J Am Heart Assoc. 2020 11 17; 9(22):e017364.
Score: 0.907
-
Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. Am J Cardiol. 2017 Oct 01; 120(7):1146-1150.
Score: 0.725
-
Hyperuricemia and Cardiovascular Disease. Rev Cardiovasc Med. 2017; 18(4):134-145.
Score: 0.698
-
Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. Am J Cardiol. 2020 12 15; 137:111-117.
Score: 0.226
-
Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study. Crit Care Explor. 2020 Sep; 2(9):e0220.
Score: 0.226
-
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2021 01; 134(1):16-22.
Score: 0.224
-
Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med. 2020 03 30; 21(1):1-7.
Score: 0.219